Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Zai Lab Q1 2026 Earnings Call - Zoci Data Strengthens Global BLA Path While Regional Revenue Faces Near-Term Pressure
Zai Lab reported a 6% year-over-year decline in Q1 2026 product revenue to $99.6 million, driven by generic competition for ZEJULA and price discounts on VYVGART, though the company expects sequential...
- Zoci demonstrated a 62.5% confirmed intracranial overall response rate in extensive-stage small cell lung cancer, with a best overall intracranial response rate approaching 69% and only 16% grade 3 or higher treatment-related adverse events, signaling a best-in-class safety and efficacy profile.
- The registrational Phase III DLLEVATE study for zoci is enrolling well and is on track to complete enrollment in the first half of 2027, positioning the company for an interim analysis and potential accelerated approval submission in 2028.
- Zai Lab announced global collaborations with Amgen and Boehringer Ingelheim to explore zoci in combination with T-cell engagers and PD-L1 inhibitors, leveraging complementary mechanisms to deepen and extend responses in small cell lung cancer.
- +12 more takeaways
Apyx Medical Q1 2026 Earnings Call - AYON Sales Surge Drives 32% Revenue Growth and Upward Guidance Revision
Apyx Medical delivered a robust first quarter, with total revenue jumping 32% year-over-year to $12.5 million, fueled by a 36% surge in surgical aesthetics sales. The AYON body contouring platform, la...
- Total revenue grew 32% year-over-year to $12.5 million, driven by a 36% increase in surgical aesthetics segment revenue to $10.7 million.
- AYON body contouring system sales are ramping rapidly, with approximately 80% of sales going to existing Renuvion customers and new accounts showing strong engagement.
- GLP-1 weight loss drug adoption is creating a structural tailwind, as patients seek surgical interventions for loose skin, with management citing early-stage adoption and significant long-term demand potential.
- +9 more takeaways
Victory Capital Q1 2026 Earnings Call - Record Flows and Aggressive Buybacks Fuel Growth
Victory Capital reported record-breaking first quarter results, driven by a massive $18.9 billion in long-term gross flows and a 77% year-over-year revenue jump to $388 million. The firm is clearly ca...
- Record Q1 2026 gross flows hit $18.9 billion, a 104% increase year-over-year, signaling strong distribution momentum.
- Total client assets reached $313 billion, with international AUM growing to $55 billion across 60 countries.
- VictoryShares ETF AUM surged 53% year-over-year to over $20 billion, with net flows of $1.3 billion for the quarter.
- +7 more takeaways
Polestar Q1 2026 Earnings Call - Record Volume Growth Amidst Margin Squeeze and Tariff Headwinds
Polestar delivered a record first quarter with 13,100 vehicles sold, marking a 7% year-over-year increase driven by strong regional performance in Europe and successful launch of the Polestar 4. The c...
- Polestar achieved record Q1 2026 deliveries of 13,100 vehicles, a 7% year-over-year increase, with Europe accounting for 78% of total sales.
- Revenue remained stable at $633 million, supported by higher volume and positive foreign exchange impacts from the pound and euro.
- Gross margin contracted to negative 3.2%, pressured by intense EV competition, pricing discounts, lower carbon credit sales, and new EU/U.S. tariffs.
- +7 more takeaways
HMH Holding Q1 2026 Earnings Call - Offshore Contracting Inflection Drives Backlog Surge and Margin Resilience
HMH Holding reported a first quarter where revenue missed the top line but margins held firm, a classic signal of a supply chain and backlog transition. The real story is the 1.3 book-to-bill ratio an...
- HMH Holding reported Q1 2026 revenue of $171 million, down 14% year-over-year, driven by lower product and service volumes as the company navigates a transitional backlog period.
- Adjusted EBITDA came in at $30 million, with margins expanding to 17.6% year-over-year, a testament to disciplined cost execution and a favorable mix in spare parts.
- Orders surged to $218 million, a 10% increase year-over-year, resulting in a book-to-bill ratio of 1.3 times and signaling a clear inflection point in customer demand.
- +7 more takeaways
DiaMedica Therapeutics Q1 2026 Earnings Call - DM199 Stroke Trial Nears Interim Analysis, Preeclampsia Pipeline Expands Amid FDA Hurdles
DiaMedica Therapeutics reported a modest increase in cash burn as it advances DM199 across two major indications, with the ReMEDy2 stroke trial crossing the 70% enrollment threshold for its planned en...
- ReMEDy2 stroke trial enrollment surpassed 70% of the target required for the interim analysis, with site activations now spanning the U.S., Canada, U.K., and six additional European countries.
- DiaMedica plans to complete the interim analysis for the stroke program by the end of 2026, with a futility check preceding any potential enrollment expansion.
- Phase II data from the prior ReMEDy1 study showed a 19% absolute improvement in functional outcomes for patients with moderate stroke severity, alongside a 50% reduction in patient deaths.
- +7 more takeaways
ACM Research Q1 2026 Earnings Call - 34% Revenue Growth Driven by AI Packaging Boom and New Product Ramp
ACM Research delivered a strong start to 2026, posting Q1 revenue of $231 million, a 34% year-over-year increase, fueled by surging demand in electroplating (ECP) and advanced packaging. Gross margin ...
- Q1 2026 revenue reached $231.3 million, up 34.2% year-over-year, driven by explosive growth in electroplating (ECP) and advanced packaging segments.
- Gross margin expanded to 46.5%, beating the midpoint of the 42%-48% long-term target range, supported by favorable product mix and lower inventory provisions.
- Shipments surged 53.6% to $240.7 million, with approximately 15% representing catch-up deliveries from Q4 2025, indicating strong backlog momentum.
- +7 more takeaways
Galapagos NV Q1 2026 Earnings Call - Rebranding to Lakefront Biotherapeutics Amid Gilead Partnership and Gamgertamig Pivot
Galapagos NV is executing a full-scale transformation, rebranding to Lakefront Biotherapeutics and securing a landmark partnership with Gilead for the Ouro Medicines portfolio. The deal centers on gam...
- Galapagos NV is rebranding to Lakefront Biotherapeutics, effective May 8, 2026, marking a full strategic transformation with a new management team and board focused on disciplined capital allocation and pipeline reshaping.
- The company secured a binding agreement with Gilead for the Ouro Medicines portfolio, centering on gamgertamig, a BCMA/CD3 T-cell engager with multi-billion-dollar revenue potential in autoimmune diseases.
- Gamgertamig has demonstrated rapid, durable complete responses with minimal cytokine release syndrome across over 60 patients in five autoimmune indications, positioning it as a potential first-in-class therapy.
- +7 more takeaways
GigaCloud Technology Q1 2026 Earnings Call - Europe Scales, New Classic Integration Begins, and Margins Show Natural Hedge
GigaCloud Technology delivered a quarter of disciplined growth that defied a soft U.S. furniture market. Revenue surged 32% to $359 million while EPS jumped 53% to $1.04. The company’s marketplace mod...
- Revenue grew 32% year-over-year to $359 million, while EPS surged 53% to $1.04, proving the resilience of the SFR marketplace model.
- GMV rose 17% year-over-year to $1.7 billion, driven by a 25% increase in active buyers and a 19% rise in active third-party sellers.
- Europe emerged as a high-growth vector, with marketplace GMV jumping 83% quarter-over-quarter and three-party seller GMV exploding over 500% year-over-year.
- +7 more takeaways
Akebia Therapeutics Q1 2026 Earnings Call - Vafseo Revenue Surges 32% as Dialysis Adherence Shifts to Observed Dosing
Akebia Therapeutics reported a strong start to 2026 with Vafseo revenue jumping 32% to $15.8 million in Q1, driven by a 60% increase in patients on therapy and broader adoption across dialysis organiz...
- Vafseo Q1 2026 net product revenue reached $15.8 million, a 32% increase year-over-year and the highest quarterly revenue since launch.
- Patient count on Vafseo grew 60% quarter-over-quarter to nearly 7,500 patients at the end of Q1 2026.
- Prescriber base expanded by 28% to approximately 1,025 prescribers, with 30% coming from dialysis organizations outside U.S. Renal Care.
- +12 more takeaways